Ivacaftor

Basic Information

CAS ID: 873054-44-5
Molecular Formula: C24H28N2O3
Molecular Weight: 392.5 g/mol
Monoisotopic Mass: 392.21 g/mol
Class: Small Molecule
Natural Product: No
Other Names: KALYDECO | VX-770 | IVACAFTOR
Analysis: Drug repositioning mechanism analysis

NH O NH O OH

Compound Structure and Identifier

InChI: InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29) See All
InChI Key: PURKAOJPTOLRMP-UHFFFAOYSA-N
Smiles: CC(C)(C)c1cc(c(NC(=O)C2=CNc3ccccc3C2=O)cc1O)C(C)(C)C See All
Molfile: Download

Related Target

Related Fibrosis Property

Reference Record 1

PubMed ID 23276841 Target ID
Uniprot ID Name
Model human Fibrosis Disease Cystic fibrosis
Process I
Process II
Process III
Mechanism

Reference Record 2

PubMed ID 19846789 Target ID
Uniprot ID Name
Model vitro Fibrosis Disease Cystic fibrosis
Process I
Process II
Process III
Mechanism

Reference Record 3

PubMed ID 29099344 Target ID
Uniprot ID Name
Model human Fibrosis Disease Cystic fibrosis
Process I
Process II
Process III
Mechanism

Trial Record 1

ClinicalTrial ID NCT02445053 Disease Cystic fibrosis
Phase Status Active, not recruiting
First Received May 15, 2015 Last Verified August 16, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 2

ClinicalTrial ID NCT01705145 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received October 12, 2012 Last Verified April 5, 2016
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 3

ClinicalTrial ID NCT01946412 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received September 19, 2013 Last Verified February 1, 2017
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 4

ClinicalTrial ID NCT01784419 Disease Cystic fibrosis
Phase Not Applicable Status Unknown
First Received February 5, 2013 Last Verified October 21, 2014
Sponsor University of California, San Francisco

Trial Record 5

ClinicalTrial ID NCT02194881 Disease Cystic fibrosis
Phase Status Completed
First Received July 18, 2014 Last Verified August 1, 2017
Sponsor Assistance Publique - Hôpitaux de Paris

Trial Record 6

ClinicalTrial ID NCT00457821 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received April 9, 2007 Last Verified October 5, 2012
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 7

ClinicalTrial ID NCT00909532 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received May 28, 2009 Last Verified January 18, 2013
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 8

ClinicalTrial ID NCT00909727 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received May 28, 2009 Last Verified August 21, 2012
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 9

ClinicalTrial ID NCT00953706 Disease Cystic fibrosis
Phase Phase 2 Status Terminated
First Received August 6, 2009 Last Verified September 11, 2015
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 10

ClinicalTrial ID NCT03227471 Disease Cystic fibrosis
Phase Phase 1,Phase 2 Status Completed
First Received July 24, 2017 Last Verified April 30, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 11

ClinicalTrial ID NCT01117012 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received May 5, 2010 Last Verified July 7, 2015
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 12

ClinicalTrial ID NCT02934698 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received October 17, 2016 Last Verified August 6, 2018
Sponsor Medical University of South Carolina

Trial Record 13

ClinicalTrial ID NCT02951195 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received November 1, 2016 Last Verified January 14, 2019
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 14

ClinicalTrial ID NCT01707290 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received October 16, 2012 Last Verified May 12, 2017
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 15

ClinicalTrial ID NCT03278314 Disease Cystic fibrosis
Phase Status -
First Received September 11, 2017 Last Verified November 2, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 16

ClinicalTrial ID NCT01685801 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received September 14, 2012 Last Verified May 19, 2015
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 17

ClinicalTrial ID NCT02951182 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received November 1, 2016 Last Verified August 15, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 18

ClinicalTrial ID NCT01262352 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received December 17, 2010 Last Verified February 11, 2013
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 19

ClinicalTrial ID NCT03029455 Disease Cystic fibrosis
Phase Phase 1 Status Completed
First Received January 24, 2017 Last Verified September 5, 2017
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 20

ClinicalTrial ID NCT02971839 Disease Cystic fibrosis
Phase Phase 2 Status Terminated
First Received November 23, 2016 Last Verified August 15, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 21

ClinicalTrial ID NCT01614457 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received June 8, 2012 Last Verified February 12, 2015
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 22

ClinicalTrial ID NCT03068312 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received March 1, 2017 Last Verified January 18, 2019
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 23

ClinicalTrial ID NCT02797132 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received June 13, 2016 Last Verified October 30, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 24

ClinicalTrial ID NCT01161537 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received July 13, 2010 Last Verified July 31, 2014
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 25

ClinicalTrial ID NCT02953314 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received November 2, 2016 Last Verified October 5, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 26

ClinicalTrial ID NCT03125395 Disease Cystic fibrosis
Phase Phase 3 Status Active, not recruiting
First Received April 24, 2017 Last Verified January 18, 2019
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 27

ClinicalTrial ID NCT01614470 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received June 8, 2012 Last Verified October 29, 2014
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 28

ClinicalTrial ID NCT01897233 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received July 11, 2013 Last Verified June 20, 2017
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 29

ClinicalTrial ID NCT02742519 Disease Cystic fibrosis
Phase Phase 3 Status Terminated
First Received April 19, 2016 Last Verified November 19, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 30

ClinicalTrial ID NCT02875366 Disease Cystic fibrosis
Phase Phase 4 Status Completed
First Received August 23, 2016 Last Verified December 2, 2017
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 31

ClinicalTrial ID NCT02725567 Disease Cystic fibrosis
Phase Phase 3 Status Recruiting
First Received April 1, 2016 Last Verified January 16, 2019
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 32

ClinicalTrial ID NCT02730208 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received April 6, 2016 Last Verified August 24, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 33

ClinicalTrial ID NCT02565914 Disease Cystic fibrosis
Phase Phase 3 Status Enrolling by invitation
First Received October 1, 2015 Last Verified November 22, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 34

ClinicalTrial ID NCT03277196 Disease Cystic fibrosis
Phase Phase 3 Status Recruiting
First Received September 8, 2017 Last Verified May 28, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 35

ClinicalTrial ID NCT01225211 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received October 20, 2010 Last Verified October 5, 2015
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 36

ClinicalTrial ID NCT02508207 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received July 24, 2015 Last Verified July 27, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 37

ClinicalTrial ID NCT01531673 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received February 13, 2012 Last Verified April 13, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 38

ClinicalTrial ID NCT02070744 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received February 25, 2014 Last Verified April 13, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 39

ClinicalTrial ID NCT02516410 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received August 5, 2015 Last Verified June 12, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 40

ClinicalTrial ID NCT02392234 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received March 18, 2015 Last Verified June 12, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 41

ClinicalTrial ID NCT02412111 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received April 8, 2015 Last Verified January 8, 2019
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 42

ClinicalTrial ID NCT01807949 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received March 8, 2013 Last Verified September 27, 2016
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 43

ClinicalTrial ID NCT01807923 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received March 8, 2013 Last Verified August 31, 2015
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 44

ClinicalTrial ID NCT01931839 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received August 29, 2013 Last Verified May 12, 2017
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 45

ClinicalTrial ID NCT02653027 Disease Cystic fibrosis
Phase Not Applicable Status Withdrawn
First Received January 12, 2016 Last Verified May 21, 2018
Sponsor Massachusetts General Hospital

Trial Record 46

ClinicalTrial ID NCT02807415 Disease Cystic fibrosis
Phase Status Recruiting
First Received June 21, 2016 Last Verified February 25, 2019
Sponsor Hannover Medical School

Trial Record 47

ClinicalTrial ID NCT03150719 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received May 12, 2017 Last Verified October 1, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 48

ClinicalTrial ID NCT01937325 Disease Cystic fibrosis
Phase Phase 4 Status Unknown
First Received September 9, 2013 Last Verified July 25, 2016
Sponsor The Alfred

Trial Record 49

ClinicalTrial ID NCT03256968 Disease Cystic fibrosis
Phase Phase 4 Status Completed
First Received August 22, 2017 Last Verified January 14, 2019
Sponsor University of Alabama at Birmingham

Trial Record 50

ClinicalTrial ID NCT03256799 Disease Cystic fibrosis
Phase Phase 4 Status Completed
First Received August 22, 2017 Last Verified October 19, 2017
Sponsor University of Alabama at Birmingham

Trial Record 51

ClinicalTrial ID NCT03061331 Disease Cystic fibrosis
Phase Phase 2 Status Completed
First Received February 23, 2017 Last Verified October 2, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 52

ClinicalTrial ID NCT02544451 Disease Cystic fibrosis
Phase Phase 3 Status Active, not recruiting
First Received September 9, 2015 Last Verified October 2, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 53

ClinicalTrial ID NCT02514473 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received August 3, 2015 Last Verified October 23, 2017
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 54

ClinicalTrial ID NCT02347657 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received January 27, 2015 Last Verified June 12, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 55

ClinicalTrial ID NCT02724527 Disease Cystic fibrosis
Phase Phase 2 Status Unknown
First Received March 31, 2016 Last Verified November 21, 2016
Sponsor Nivalis Therapeutics, Inc.

Trial Record 56

ClinicalTrial ID NCT02858843 Disease Cystic fibrosis
Phase Not Applicable Status Terminated
First Received August 8, 2016 Last Verified May 21, 2018
Sponsor Massachusetts General Hospital

Trial Record 57

ClinicalTrial ID NCT02390219 Disease Cystic fibrosis
Phase Phase 3 Status Completed
First Received March 17, 2015 Last Verified December 6, 2017
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 58

ClinicalTrial ID NCT02823470 Disease Cystic fibrosis
Phase Phase 4 Status Terminated
First Received July 6, 2016 Last Verified September 27, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 59

ClinicalTrial ID NCT02310789 Disease Cystic fibrosis
Phase Not Applicable Status Completed
First Received December 8, 2014 Last Verified January 9, 2019
Sponsor Richard Barry Moss

Trial Record 60

ClinicalTrial ID NCT02015507 Disease Cystic fibrosis
Phase Phase 1 Status Completed
First Received December 19, 2013 Last Verified March 26, 2014
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 61

ClinicalTrial ID NCT01910415 Disease Cystic fibrosis
Phase Phase 1 Status Completed
First Received July 29, 2013 Last Verified August 11, 2014
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 62

ClinicalTrial ID NCT01899105 Disease Cystic fibrosis
Phase Phase 1 Status Completed
First Received July 15, 2013 Last Verified April 3, 2014
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 63

ClinicalTrial ID NCT01768663 Disease Cystic fibrosis
Phase Phase 1 Status Completed
First Received January 15, 2013 Last Verified November 15, 2013
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 64

ClinicalTrial ID NCT01381289 Disease Cystic fibrosis
Phase Status -
First Received June 27, 2011 Last Verified February 9, 2012
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 65

ClinicalTrial ID NCT01216046 Disease Cystic fibrosis
Phase Phase 1 Status Completed
First Received October 7, 2010 Last Verified January 18, 2012
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 66

ClinicalTrial ID NCT01060566 Disease Cystic fibrosis
Phase Phase 1 Status Completed
First Received February 2, 2010 Last Verified April 16, 2010
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 67

ClinicalTrial ID NCT01018368 Disease Cystic fibrosis
Phase Phase 1 Status Completed
First Received November 23, 2009 Last Verified May 10, 2010
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 68

ClinicalTrial ID NCT00966602 Disease Cystic fibrosis
Phase Phase 1 Status Completed
First Received August 27, 2009 Last Verified January 5, 2010
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 69

ClinicalTrial ID NCT01208285 Disease Cystic fibrosis
Phase Phase 1 Status Completed
First Received September 23, 2010 Last Verified January 12, 2011
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 70

ClinicalTrial ID NCT01153542 Disease Cystic fibrosis
Phase Phase 1 Status Completed
First Received June 30, 2010 Last Verified December 9, 2010
Sponsor Vertex Pharmaceuticals Incorporated

Trial Record 71

ClinicalTrial ID NCT02039986 Disease Cystic fibrosis
Phase Status Completed
First Received January 20, 2014 Last Verified December 14, 2018
Sponsor Children's Hospital of Philadelphia

Trial Record 72

ClinicalTrial ID NCT02722057 Disease Cystic fibrosis
Phase Status Active, not recruiting
First Received March 29, 2016 Last Verified August 14, 2018
Sponsor Vertex Pharmaceuticals Incorporated

Related Link

PubChem: 16220172
ChEMBL: CHEMBL2010601